这一期《月度好文精选》来晚啦，因为药药忙着处理「专业版拼团」活动的用户反馈。虽然晚了一些，但我保证，这一期好文章绝对超值！8 月用药经验 TOP 5《临床医生...给药？》《五张表教你同类药物如何等效剂量换算》8 月用药问答 TOP 5《用药问答：输液时突然休克，谁是罪魁祸首？》《用药问答：急诊遇糖尿病急性并发症

2017 年 6 月 13 日，备受瞩目的 2016 SCI 期刊影响因子正式发布，儿科领域的各期刊的 IF 值有何变化？一起来看下吧。儿科领域 Top 10...。儿科领域Top 30至于第 19 名，儿科君搜了去年的前 50 也没找到，只能说是一匹黑马。。。具体查询方法进入网站：web of science

界面：依次选中 Data1：C：C，Reorder，Up 三个选项至 Data1：C：C 上升至第一列，再点击 OK（或者直接点击 Top，置于顶端也可以得到... 下移，Top 置于顶端，Bottom 置于底端，Reverse 反转数据列顺序（即顺序有 ABCDE 改变为 EDCBA）。此外，进入 Format Graph

推荐书」的 TOP.5 榜单吧！这是根据「医生阅读行为」调研活动中的 2102 份有效问卷得出的榜单，有很多医生推荐同行看这些书。看了医生推荐的 Top

、生物技术类药物、神经系统药物、抗感染药物和复方药物为排名居 TOP 5 的治疗领域。其中，癌症仍是药品研发的核心领域，抗癌/抗肿瘤药物数量呈现显著增长态势，数量...，与 2015 年数据进行对比，可反映不同治疗类别在研药物数量的变化情况。从治疗类别 TOP 25 排名中发现，一般抗癌药 (在研药物 2071 个)、免疫类

已出，评论区可回答延伸问题赢奖励）>>上期问答：变异型心绞痛临床用药首选？【延伸问题】急性胰腺炎内科治疗如何用药？答案：急诊之急性胰腺炎（AP

或继发微循环障碍破坏了胰腺间质细胞内的屏障防护作用 , 从而启动胰腺的自身消化机制 , 引发炎症。明确可引起药源性胰腺炎的药物包括：由于不同药物引起 AP 的机制不同, 即使同一药物对不同个体的致病过程和程度亦常有较大差异。目前 DAP 多为个例报道，因致病药物的类别和病人机体状况的差异, 不少人缺乏 AP 典型的腹痛

（AP）调节异常的结果。C3 肾小球病包括 C3 肾炎和致密物沉积病（DDD）。在补体介导 GN（C3 肾小球肾病）中，C3 染色明亮，Ig 染色通常阴性。然而... 例）C4d 染色痕量或 1+。至于感染后 GN，46%（6 例）的样本 C4d 染色阴性，提示 AP 途径不正常，54%（7 例）的样本阳性。（见图 1）图 1

of RhoA, Rac1 and AP-1 transcriptional activity. Taken together, our results

的前后(AP)径和椎板开门的角度。术前、术后1年通过MRI检查来评价脊髓压迫的严重程度。结果发现，椎管的前后径和椎板开门的角度虽在术后立即增加(均P

会议简介

According to Business Insights, an estimated $25bn worth of biologics will lose patent protection by 2016, creating a significant market opportunity for biosimilars. However, the reality is that biosimilar development is a risk-fraught activity that demands significant resources in R&D, manufacturing expertise, regulatory know-how, clinical-trial capabilities, and a high level of financial investment.

Biosimilar development is riddled with complexities, ranging from regulatory, to manufacturing to marketing, and is one of the most expensive propositions in the pharmaceutical industry. It is estimated that it costs between US$100-200 million to bring a biosimilar product to market. With so much at stake, biosimilars represent not only substantial growth but equally risk..

IBC’s 2nd Annual Biosimilars Asia 2011 Summit is the ONLY conference in Asia catering to this region’s specific queries. With unprecedented insights from leading innovators and biosimilar companies, you will network and learn how to strategically position your company to maximize your ROI. Biosimilars Asia 2011 is attended by key stakeholders in the region and beyond, enabling you to make informed strategic decisions.

Register Now

PAYMENT TERMS

Payment must be received 10 business days prior to the event. To take advantage of discounts with an expiry cut-off date, registration and payment must be received by the cut off date.

Payments by Singapore Dollars (S$)

Payments by RMB (CNY)

• Payment by telegraphic transfer in CNY must be made to:
  A/C Name:
  A/C No.: 720-031103-001
  Beneficiary Bank:
  Bank Address: No. 1000 Lujiazui Rind Road,
  Pudong, Shanghai 200120, P.R. China
  Bank Swift Code: HSBCCNSH

CANCELLATIONS SUBSTITUTION
Should you be unable to attend, a substitute delegate is welcome at no extra charge. Cancellations must be received in writing at least 10 business days before the start of the event, to receive a refund less 10% processing fee per registration. The company regrets that no refund will be made available for cancellation notifications received less than 10 business days before the event.IMPORTANT NOTE:
Please quote the name of the delegate, event title and invoice number on the advice when remitting payment. Bank charges are to be deducted from participating organisations own accounts. Please fax your payment details (copy of remittance advice, cheque or draft to +65 6508 2407.

Attendance will only be permitted upon receipt of full payment. Participants wishing to register at the door are responsible to ensure all details are as published. IBC Asia will not be responsible for any event re-scheduled or cancelled.


DATA PROTECTION
The personal information entered during your registration/order, or provided by you, will be held on a database and may be shared with companies in the Informa Group in the UK and internationally. Sometimes your details may be obtained from or shared with external companies for marketing purposes. If you do not wish your details to be used for this purpose, please contact Winnie Seah (Database) on winnie.seah@ibcasia.com.sg Tel: +65 6508 2468 or Fax: +65 6508 2408.

【今日问答】甲亢性心脏病的老年患者,甲状腺功能亢进的治疗首选？A.复方碘溶液B.大剂量普萘洛尔C.抗甲状腺药物D.核素131I治疗E.立即行甲状腺手术解析...131I禁忌者（C）；复方碘溶液仅在甲亢手术前和甲状腺危象时使用（A）。大剂量普萘洛尔对甲亢性心脏病有益，但非首选药物（B）。甲状腺手术为创伤性措施，非首选，但凡疑是

成为治疗脑瘫的有效措施，给更多患者带来福音」。甲亢碘-131 治疗剂量再优化 颜兵 北京霍普医院院长、核医学科主任、中国非公立医疗机构协会甲状腺专业委员会副主任委员、中华医学会核医学分会治疗学组委员颜兵院长详细阐述了新技术在精准测量甲状腺体积、精准估算碘-131 有效半衰期、以及个体化碘-131 剂量再优化中的临床医学

of Surgical Oncology上。研究纳入了国立九州癌症中心2003年——2008年131名前哨淋巴结（SLN）阳性患者，均行腋窝淋巴结清扫，评估其长期预后及非前哨淋巴结转移情况。统计结果显示：在131名患者中，46名（35%）ECI阳性。其中，61%非前哨淋巴结转移，而ECI阴性组为28%。多变量分析显示

本期「TOP list ·月度案例评选」是基于 6 月在丁香园医院汇平台上发布的文章，根据阅读量及点赞量呈现医疗行业「最受欢迎的品牌案例」TOP 10。医院汇努力为医疗行业从业者打造优秀品牌案例库，供行业宣传人士参考学习，也是众医院打造品牌曝光的重要营地。新闻资讯 TOP 10排名医院